Salvage treatment with apatinib for advanced non-small-cell lung cancer

Figures & data

Table 1 Clinical characteristics of the study population (n=42)

Variables	Number (%)
Gender
Male	24 (57.1)
Female	18 (42.9)
PS
0–1	25 (59.5)
2	17 (40.5)
Age, years
Median (range)	56.5 (42–75)
>60	10 (23.8)
≤60	32 (76.2)
Smoking history
Yes	17 (40.5)
No	25 (59.5)
Histology
Adenocarcinoma	30 (71.4)
Squamous cell carcinoma	12 (28.6)
EGFR mutation
Yes	7 (16.7)
No	11 (26.2)
Unknown	24 (57.1)
Line of apatinib therapy
Third line	19 (45.2)
Further line	23 (54.8)
Targeted treatment in prior therapy
Yes	29 (69.0)
No	13 (31.0)

Abbreviation: PS, performance status.

Figure 1 Kaplan–Meier estimates of progression-free survival of apatinib treatment.

Figure 2 Kaplan–Meier estimates of overall survival of apatinib treatment.

Table 2 Univariate analysis of PFS and OS

	PFS	95% CI	P-value	OS	95% CI	P-value
Gender			0.06			0.12
Male	2.5	1.4–3.6		5.2	3.2–5.7
Female	10.0	4.7–12.3		10.7	5.1–14.1
Age, years			0.13			0.21
>60	7.0	1.2–12.3		4.2	1.5–5.5
≤60	1.2	0.4–2.0		6.5	4.2–7.9
PS			0.07			0.09
0–1	10.0	1.2–13.5		8.5	5.4–14.2
2	3.0	0.5–5.5		4.5	3.0–6.8
Line of therapy			0.43			0.31
Third–line	2.5	0.0–8.4		7.2	3.8–10.5
Further-line	8.0	0.1–12.9		5.5	4.0–7.7
Smoking history			0.34			0.47
Yes	2.5	1.5–3.5		5.5	3.0–8.5
No	8.0	5.2–10.8		7.8	6.0–10.5
Histology			0.36			0.17
Adenocarcinoma	7.0	0.0–12.6		6.5	0.3–12.7
Squamous cell	1.9	0.0–5.0		4.3	2.1–8.5
EGFR status			0.25			0.87
Mutation	4.4	0.6–4.8		7.0	5.0–9.5
Wild-type	4.0	1.0–6.0		5.5	4.0–6.5
Prior treatment efficacy			0.42			0.55
Responder	4.6	1.2–6.2		7.5	3.5–10.0
Nonresponder	3.5	0.0–5.0		5.0	2.5–9.0

Abbreviations: PFS, progression-free survival; OS, overall survival; PS, performance status.

Table 3 Main grade 3/4 toxicities of apatinib treatment

Toxicity	Grades 3–4	Percentage
Hand–foot syndrome	6	14.3
Hypertension	4	9.5
Proteinuria	3	7.1
Hepatic injure	3	7.1
Fatigue	2	4.8
Nausea/vomiting	2	4.8
Febrile neutropenia	1	2.4
Anemia	1	2.4